Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
2.360
+0.050 (2.16%)
At close: May 29, 2026, 4:00 PM EDT
2.400
+0.040 (1.69%)
After-hours: May 29, 2026, 7:51 PM EDT
Caribou Biosciences Revenue
Caribou Biosciences had revenue of $2.40M in the quarter ending March 31, 2026, with 1.87% growth. This brings the company's revenue in the last twelve months to $11.20M, up 12.96% year-over-year. In the year 2025, Caribou Biosciences had annual revenue of $11.16M with 11.66% growth.
Revenue (ttm)
$11.20M
Revenue Growth
+12.96%
P/S Ratio
20.89
Revenue / Employee
$115,495
Employees
97
Market Cap
234.07M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.16M | 1.17M | 11.66% |
| Dec 31, 2024 | 9.99M | -24.48M | -71.01% |
| Dec 31, 2023 | 34.48M | 20.63M | 148.91% |
| Dec 31, 2022 | 13.85M | 4.25M | 44.31% |
| Dec 31, 2021 | 9.60M | -2.76M | -22.35% |
| Dec 31, 2020 | 12.36M | 6.57M | 113.56% |
| Dec 31, 2019 | 5.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arcturus Therapeutics Holdings | 54.71M |
| Voyager Therapeutics | 36.49M |
| Orchestra BioMed Holdings | 32.72M |
| Sol-Gel Technologies | 18.47M |
| Alector | 18.42M |
| Whitehawk Therapeutics | 7.15M |
| Camp4 Therapeutics | 3.93M |
| YD Bio | 510.36K |
CRBU News
- 4 days ago - Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 12 days ago - Caribou Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 18 days ago - Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference - GlobeNewsWire
- 18 days ago - Caribou Biosciences Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 19 days ago - Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting - GlobeNewsWire
- 20 days ago - Caribou Biosciences price target raised to $11 from $9 at H.C. Wainwright - TheFly
- 24 days ago - Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 24 days ago - Caribou Biosciences Quarterly report: Q1 2026 - Filings